Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Belluscura shares surge on strong sales momentum, improved outlook
(Sharecast News) - Belluscura, a developer of lightweight and portable oxygen enrichment technology, reported strong sales momentum and an optimistic trading outlook on Tuesday, as it prepared for the full commercial launch of its new 'DISCOV-R' portable oxygen concentrator. The AIM-traded firm, which was holding its annual general meeting, highlighted a significant increase in sales and a positive forecast for the rest of 2024.
It said that it achieved record sales in July, generating $0.71m in revenue, surpassing the previous high of $0.52m set in June.
The company expected the strong sales trajectory to continue, driven by growing market acceptance of its X-PLOR device and the anticipated success of the DISCOV-R, which was introduced to the US market via a soft launch in June.
It said the DISCOV-R portable oxygen concentrator, which weighs just over six pounds, offered 50% more oxygen output than the leading competitor and produced more oxygen by weight than any other portable device on the market.
The strong demand for the DISCOV-R was reportedly evident, with all units produced in June and July already sold.
Belluscura said a full commercial launch of the device was scheduled for the middle of the fourth quarter.
Given the promising market response and the upcoming launch of the DISCOV-R, Belluscura updated its trading outlook for the final months of 2024.
The company said it now anticipated full-year revenue for 2024 to be between $8m and $10m - a substantial increase from $0.83m in 2023.
Furthermore, the company expected to achieve positive EBITDA in the first quarter of the 2025 financial year, with an annualised revenue run rate of $14m to $16m by the end of the year.
To support the ongoing expansion and meet the high customer demand for the DISCOV-R, Belluscura said it was evaluating various financing options, including debt and credit facilities.
The company noted that, while increased sales of the X-PLOR units had reduced raw materials inventory, securing additional funding would be crucial to sustaining the growth of the DISCOV-R.
At 1216 BST, shares in Belluscura were up 43.86% at 15.82p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
